Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-04447943 (Edelinontrine) 是一种有效且具有选择性的的磷酸二酯酶 9A 抑制剂,IC50 为 12 nM,比作用于其他PDE家族成员选择性高 78 倍 (IC50<1000 nM)。PF-04447943 具有抗炎活性,通过抑制氧化应激、炎症和调节T细胞极化来减轻炎症反应,且可用于研究镰刀型贫血症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 247 | 现货 | ||
5 mg | ¥ 855 | 现货 | ||
10 mg | ¥ 1,350 | 现货 | ||
25 mg | ¥ 2,850 | 现货 | ||
50 mg | ¥ 4,270 | 现货 | ||
100 mg | ¥ 5,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 939 | 现货 |
产品描述 | PF-04447943 (Edelinontrine) is a potent and selective phosphodiesterase 9A inhibitor with an IC50 of 12 nM, which is 78-fold more selective than that used for other PDE family members (IC50>1000 nM).PF-04447943 exhibits anti-inflammatory activity, attenuates inflammatory responses by inhibiting oxidative stress, inflammation, and modulating T-cell polarization, and may be useful for research on sickle cell anemia. |
靶点活性 | PDE9A:12 nM |
体外活性 | PF-04447943 inhibits ANP (0.3 μM) stimulated cGMP (IC50: 375±36.9 nM (n=16)), in HEK whole cells expressing rhesus PDE9A2. PF-04447943 is found to be highly selective over other PDE enzymes (PDE1, Ki=8600±2121 nM, n = 5; PDE2A3, Ki>99,000 nM; PDE3A, Ki>50,000 nM; PDE4A, Ki>29,000 nM; PDE5A, Ki=14,980±5025 nM, n=5; PDE6C, Ki=5324±2612 nM, n=4; PDE7A2, Ki>75,000 nM; PDE8A, Ki>50,000 nM; PDE10, Ki>51,250±20,056 nM, n=4; PDE11, Ki>80,000 nM) and no other significant activity at ~60 other receptors/enzymes. Using recombinant human, rhesus, and rat PDE9A2 in a cell-free assay PF-04447943 is shown to have a Ki of 2.8±0.26, 4.5±0.13, and 18.1±1.9 nM (n=4, 11 and 9 respectively).[2] |
体内活性 | PF-04447943 concentrations dose-dependently increase in blood, brain, and cerebrospinal fluid (CSF), thirty minutes following oral administration in rats (1-30 mg/kg). In mice, PF-04447943 (3, 10, 30 mg/kg p.o.) dose-dependently enhances plasma and brain concentrations of PF-04447943 while the brain-to-plasma ratio ranged from 0.26 to 0.7 although this is not entirely dosed-dependent. Based on i.v. and p.o. dosing, pharmacokinetic studies with PF-04447943 in the rat indicate a Tmax of 0.3 h, T1/2 of 4.9 h, Cl of 21.7 mL/min/kg, and oral bioavailability of 47%. The brain: plasma exposure ratios 30 min after dosing range from 0.13 at the 1 mg/kg dose to 0.33 at the 30 mg/kg dose. CSF levels are approximately 50% of brain levels. CSF cGMP levels increase in a dose-dependent manner from a basal level of 3 pmol/mL to 13.3 pmol/mL (3.5-fold) at the 30 mg/kg dose. CSF cGMP levels also increased in a dose-dependent manner from a basal level of 3 pmol/mL in vehicle-treated animals to 13.3 pmol/mL (3.5-fold) at the 30 mg/kg dose. CSF cGMP levels are elevated at all doses tested with a maximal effect of 3.5 fold increase above controls at 30 mg/kg.[2] |
别名 | PF 04447943, Edelinontrine, PF04447943 |
分子量 | 395.46 |
分子式 | C20H25N7O2 |
CAS No. | 1082744-20-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 39.55 mg/mL (100 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5287 mL | 12.6435 mL | 25.287 mL | 63.2175 mL |
5 mM | 0.5057 mL | 2.5287 mL | 5.0574 mL | 12.6435 mL | |
10 mM | 0.2529 mL | 1.2644 mL | 2.5287 mL | 6.3218 mL | |
20 mM | 0.1264 mL | 0.6322 mL | 1.2644 mL | 3.1609 mL | |
50 mM | 0.0506 mL | 0.2529 mL | 0.5057 mL | 1.2644 mL | |
100 mM | 0.0253 mL | 0.1264 mL | 0.2529 mL | 0.6322 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-04447943 1082744-20-4 Metabolism PDE PF 04447943 Edelinontrine PF04447943 Inhibitor inhibitor inhibit